Treatment of Secondary Hyperparathyroidism in the Uremic Patient

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients.

NCT02895061

Alfacalcidol, Secondary Hyperparathyroidism, Hemodialysis

COMPLETED NA

Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects

NCT00664430

Secondary Hyperparathyroidism Dialysis

TERMINATED PHASE4

A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism

NCT01653379

Secondary Hyperparathyroidism

COMPLETED PHASE2

Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis

NCT00667576

Chronic Kidney Disease on Hemodialysis Secondary Hyperparathyroidism

COMPLETED PHASE2

Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis

NCT00537979

Secondary Hyperparathyroidism Dialysis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Secondary hyperparathyroidism is a common feature in patients with chronic kidney disease. Its clinical consequences include renal osteodystrophy, calciphylaxia and potentially vascular calcifications with increased morbidity and mortality.

Reduced synthesis of active vitamin D contributes to secondary hyperparathyroidism. Therefore we primarily manage this condition with activated vitamin D. In Denmark alfacalcidol is the primary choice of vitamin D analog.

However hypercalcemia and hyperphosphatemia may limit the use of alfacalcidol therapy due to increased risk of vascular calcification and mortality.

Therefore a new vitamin D analog, paricalcitol, has been developed, that may be less prone to develop hypercalcemia and hyperphosphatemia.

However a randomised controlled clinical study comparing alfacalcidol and paricalcitol has never been performed.

The primary objective of this study is to evaluate the effect of alfacalcidol and paricalcitol on intact parathyroid hormone level and the tendency towards hyperphosphatemia and hypercalcemia.

The study is performed in 117 patients with end stage renal failure on maintenance hemodialysis therapy in 6 different Danish hemodialysis units.

The design is a multicenter crossover study where patients are randomized into two treatment arms. After a wash out period of 6 weeks they are receiving alfacalcidol or paricalcitol for a period of 16 weeks and after a further wash out period of 6 weeks they receive the contrary treatment (respectively paricalcitol or alfacalcidol) for 16 weeks.

The initial dose of alfacalcidol (1 μg intravenously after dialysis) and paricalcitol (3 μg intravenously after dialysis) will be adjusted every second week based on iPTH, p-calcium and p-phosphate.

P-calcium, p-phosphate, iPTH, pulse and blood pressure are measured every second week. By the beginning and the end of each period of treatment, alkaline phosphatase, 25OH-D3, 1,25 (OH)2 vitamin D and safety parameters are measured, pulse wave velocity and pulse wave analysis is performed in a subgroup.

Alfacalcidol and paricalcitol are both registered treatment modalities for patients with renal failure and secondary hyperparathyroidism and should not perform any risk for the safety of the enrolled patients as well as the blood sampling and blood pressure measurement should not perform any risk either.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Secondary Hyperparathyroidism Chronic Kidney Disease Vitamin D Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

alfacalcidol 16 weeks, 6 weeks wash out, paricalcitol 16 weeks

Group Type ACTIVE_COMPARATOR

paricalcitol

Intervention Type DRUG

3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate

2

paricalcitol ´16 weeks, 6 weeks wash out, alfacalcidol 16 weeks

Group Type ACTIVE_COMPARATOR

alfacalcidol

Intervention Type DRUG

1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

paricalcitol

3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate

Intervention Type DRUG

alfacalcidol

1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zemplar

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. \>18 years old
2. Secondary hyperparathyroidism; iPTH \> 350 pg/ml before any treatment or after 6 weeks without any treatment with vitamin D.
3. Chronic renal insufficiency receiving hemodialysis.
4. P-phosphate \< 1,8 mmol/l
5. P-calcium ion \< 1,25 mmol/l
6. Receiving maximal possible dose of calcium-based phosphate binder.
7. Accepting 2 x 6 weeks without vitamin D.
8. Safe anti conception in fertile women
9. Do not expect need of calcimimetics or parathyroidectomy during the next year.
10. Written informed consent.

Exclusion Criteria

1. Malignancy
2. Disease or condition making the patient unable to participate
3. Expected lifetime less than one year.
4. Pregnancy and nursing
5. Allergic to contents of Zemplar or Etalpha
6. Currently receiving calcimimetics
7. Participating in other clinical intervention studies

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No